UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report
of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16
Under the Securities Exchange Act of 1934
For the Month of July 2018
333-206723
(Commission File Number)
P.V. Nano Cell Ltd.
(Exact name of Registrant as specified in its charter)
8
Hamasger Street
Migdal Ha’Emek, Israel 2310102
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover
Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by
Regulation S-T Rule 101(b)(7): ____
On July 2nd, 2018, P.V. Nano Cell Ltd. (the “Issuer”) issued a press release announcing the signature of a supply agreement with Merck. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
1 |
Exhibit Index
Exhibit No. | Description | |
99.1 | PV Nano Cell and Merck Sign a Supply Agreement for Sicrys |
2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date July 2, 2018 | P.V. Nano Cell Ltd. | |
By: | /s/ Fernando de la Vega | |
Name: Dr. Fernando de la Vega | ||
Title: Chief Executive Officer |
3